EP2847197A4 - PRODRUGS OF ANTIBODY AGENTS - Google Patents

PRODRUGS OF ANTIBODY AGENTS

Info

Publication number
EP2847197A4
EP2847197A4 EP13787471.5A EP13787471A EP2847197A4 EP 2847197 A4 EP2847197 A4 EP 2847197A4 EP 13787471 A EP13787471 A EP 13787471A EP 2847197 A4 EP2847197 A4 EP 2847197A4
Authority
EP
European Patent Office
Prior art keywords
antiplaquetary
prodrugs
agents
antiplaquetary agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13787471.5A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2847197A1 (en
Inventor
Mahesh Kandula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellix Bio Pvt Ltd
Original Assignee
Cellix Bio Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2012/053673 external-priority patent/WO2013024376A1/en
Application filed by Cellix Bio Pvt Ltd filed Critical Cellix Bio Pvt Ltd
Publication of EP2847197A1 publication Critical patent/EP2847197A1/en
Publication of EP2847197A4 publication Critical patent/EP2847197A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EP13787471.5A 2012-05-07 2013-03-24 PRODRUGS OF ANTIBODY AGENTS Withdrawn EP2847197A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1781CH2012 2012-05-07
PCT/IB2012/053673 WO2013024376A1 (en) 2011-08-16 2012-07-19 Compositions and methods for the treatment of atherothrombosis
PCT/IB2013/052328 WO2013168024A1 (en) 2012-05-07 2013-03-24 Prodrugs of anti-platelet agents

Publications (2)

Publication Number Publication Date
EP2847197A1 EP2847197A1 (en) 2015-03-18
EP2847197A4 true EP2847197A4 (en) 2015-11-04

Family

ID=54193687

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13787471.5A Withdrawn EP2847197A4 (en) 2012-05-07 2013-03-24 PRODRUGS OF ANTIBODY AGENTS

Country Status (8)

Country Link
EP (1) EP2847197A4 (https=)
JP (1) JP2015519334A (https=)
CN (1) CN104379589A (https=)
AU (1) AU2013257745A1 (https=)
CA (1) CA2873094A1 (https=)
SG (1) SG11201407307YA (https=)
WO (1) WO2013168024A1 (https=)
ZA (1) ZA201408064B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201407328TA (en) * 2012-07-03 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of moderate to severe pain
CN119033782B (zh) * 2020-07-29 2025-04-25 上海柯君医药科技有限公司 抗血小板药物和其用途
CN114507157B (zh) * 2020-11-17 2023-03-24 沧州维智达美制药有限公司 一种利用氯乙腈制备溴乙腈的方法
CN119019320B (zh) * 2024-10-29 2025-03-11 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094374A2 (en) * 2003-04-23 2004-11-04 Rhodia Pharma Solutions Inc. (Formally Rhodia Chirex Inc.) Preparation of (s)-clopidogrel and related compounds
EP1889835A1 (en) * 2005-05-27 2008-02-20 Daiichi Sankyo Company, Limited Cyclic amine derivative having substituted alkyl group
WO2013024376A1 (en) * 2011-08-16 2013-02-21 Mahesh Kandula Compositions and methods for the treatment of atherothrombosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101123878A (zh) * 2003-07-29 2008-02-13 信号研发控股有限责任公司 氨基酸前药
KR100990949B1 (ko) * 2008-06-09 2010-10-29 엔자이텍 주식회사 클로피도그렐 및 그의 유도체의 제조방법
CN102002053A (zh) * 2009-09-02 2011-04-06 陕西合成药业有限公司 用于治疗的四氢噻吩并吡啶衍生物
CN102336767A (zh) * 2011-07-11 2012-02-01 华东理工大学 制备高纯度手性α-取代-6,7-二氢噻吩并[3,2-c]吡啶衍生物的方法
US9525998B2 (en) * 2012-01-06 2016-12-20 Qualcomm Incorporated Wireless display with multiscreen service
JP6097766B2 (ja) * 2012-01-27 2017-03-15 インターデイジタル パテント ホールディングス インコーポレイテッド マルチキャリアベースおよび／または疑似照合ネットワークにおいてｅｐｄｃｃｈを提供するためのシステムおよび／または方法
WO2013167985A1 (en) * 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
SG11201407317SA (en) * 2012-05-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for suppression of carbonic anhydrase activity
WO2013167987A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of diabetes
JP2015526385A (ja) * 2012-05-08 2015-09-10 セリックスビオ プライヴェート リミテッド てんかんの治療のための組成物及び方法
CA2872976A1 (en) * 2012-05-08 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
SG11201407328TA (en) * 2012-07-03 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of moderate to severe pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094374A2 (en) * 2003-04-23 2004-11-04 Rhodia Pharma Solutions Inc. (Formally Rhodia Chirex Inc.) Preparation of (s)-clopidogrel and related compounds
EP1889835A1 (en) * 2005-05-27 2008-02-20 Daiichi Sankyo Company, Limited Cyclic amine derivative having substituted alkyl group
WO2013024376A1 (en) * 2011-08-16 2013-02-21 Mahesh Kandula Compositions and methods for the treatment of atherothrombosis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEN J. F. ET AL.: "Synthesis of clopidogrel analogues and their antiplatelet aggregation actvities", HECHENG HUAXUE, vol. 18, no. 5, 1 January 2010 (2010-01-01), pages 586 - 590, XP009186089 *
M. KAZUI ET AL: "Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite", DRUG METABOLISM AND DISPOSITION, vol. 38, no. 1, 1 January 2010 (2010-01-01), pages 92 - 99, XP055020943, ISSN: 0090-9556, DOI: 10.1124/dmd.109.029132 *
PATRICK M. DANSETTE ET AL: "Formation and Fate of a Sulfenic Acid Intermediate in the Metabolic Activation of the Antithrombotic Prodrug Prasugrel +", CHEMICAL RESEARCH IN TOXICOLOGY, vol. 23, no. 7, 19 July 2010 (2010-07-19), pages 1268 - 1274, XP055020962, ISSN: 0893-228X, DOI: 10.1021/tx1001332 *
SANGKUHL KATRIN ET AL: "Clopidogrel pathway", PHARMACOGENETICS AND GENOMICS, vol. 20, no. 7, 1 July 2010 (2010-07-01), LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, PA, US, pages 463 - 465, XP009171644, ISSN: 1744-6872, DOI: 10.1097/FPC.0B013E3283385420 *
See also references of WO2013168024A1 *

Also Published As

Publication number Publication date
SG11201407307YA (en) 2014-12-30
AU2013257745A1 (en) 2014-11-27
JP2015519334A (ja) 2015-07-09
WO2013168024A1 (en) 2013-11-14
EP2847197A1 (en) 2015-03-18
ZA201408064B (en) 2016-04-28
CA2873094A1 (en) 2013-11-14
CN104379589A (zh) 2015-02-25

Similar Documents

Publication Publication Date Title
EP2940131A4 (en) AAV VARIANT
ME03359B (me) 2 suptiтuisana cefemska jedinjenja
EP2807694A4 (en) Microstructured Electrode Structures
EP2838909A4 (en) TARGETED THERAPEUTICS
EP2859439A4 (en) CLOUD APPLICATION DEPLOYMENT
EP2705091A4 (en) Polyethylene terephthalate GRAPH-NANO COMPOSITES
EP2932296A4 (en) PICTURING SUB-SURFACE RADAR
EP2864479A4 (en) MODULATION OF THE UBE3A ATS EXPRESSION
EP2628435A4 (en) insertion
EP2895174A4 (en) PRODRUGS OF AN AMINOCHINAZOLININE INHIBITOR
EP2934510A4 (en) LFA-1 INHIBITORS FORMULATIONS
EP2875415A4 (en) DISPLAY ARRANGEMENT
IL229081A0 (en) Isoxazolines as therapeutic agents
SMT201600441B (it) Nuovi agenti antimalarici
EP2844171A4 (en) OUTPUT OF FASTENERS
PT2836483T (pt) Agentes antimalária
EP2832476A4 (en) PROCESSING DEVICE
EP2739764A4 (en) ION SOURCE
EP2699671A4 (en) INFLAMMATORY ACTIVE SUBSTANCES
EP2931042A4 (en) ANTHRACYCLINFORMULIERUNGEN
DK2917212T3 (da) Antimikrobielle midler
BR302012001925S1 (pt) "configuração aplicada em calota"
EP2847197A4 (en) PRODRUGS OF ANTIBODY AGENTS
EP2853308A4 (en) AERATOR
BR302012006162S1 (pt) "configuração aplicada em cartucho"

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 7/02 20060101ALI20150923BHEP

Ipc: C07D 495/04 20060101AFI20150923BHEP

Ipc: C07D 211/72 20060101ALI20150923BHEP

Ipc: A61P 9/00 20060101ALI20150923BHEP

Ipc: A61P 25/00 20060101ALI20150923BHEP

Ipc: A61K 31/445 20060101ALI20150923BHEP

Ipc: A61K 31/4365 20060101ALI20150923BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20151002

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 211/72 20060101ALI20150928BHEP

Ipc: A61P 25/00 20060101ALI20150928BHEP

Ipc: C07D 495/04 20060101AFI20150928BHEP

Ipc: A61K 31/445 20060101ALI20150928BHEP

Ipc: A61P 7/02 20060101ALI20150928BHEP

Ipc: A61P 9/00 20060101ALI20150928BHEP

Ipc: A61K 31/4365 20060101ALI20150928BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20160511